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Tau-tubulin kinase (TTBK) belongs to casein kinase superfamily and phosphorylates
microtubule-associated protein tau and tubulin.TTBK has two isoforms,TTBK1 andTTBK2,
which contain highly homologous catalytic domains but their non-catalytic domains are
distinctly different. TTBK1 is expressed speciﬁcally in the central nervous system and is
involved in phosphorylation and aggregation of tau. TTBK2 is ubiquitously expressed in
multiple tissues and genetically linked to spinocerebellar ataxia type 11. TTBK1 directly
phosphorylates tau protein, especially at Ser422, and also activates cycline-dependent
kinase 5 in a unique mechanism. TTBK1 protein expression is signiﬁcantly elevated in
Alzheimer’s disease (AD) brains, and genetic variations of the TTBK1 gene are associated
with late-onset Alzheimer’s disease in two cohorts of Chinese and Spanish populations.
TTBK1 transgenic mice harboring the entire 55-kilobase genomic sequence of human
TTBK1 show progression of tau accumulation, neuroinﬂammation, and neurodegeneration
when crossed with tau mutant mice. Our recent study shows that there is a striking switch
in mononuclear phagocyte and activation phenotypes in the anterior horn of the spinal
cord from alternatively activated (M2-skewed) microglia in P301L tau mutant mice to pro-
inﬂammatory (M1-skewed) inﬁltrating peripheral monocytes by crossing the tau mice with
TTBK1 transgenic mice.TTBK1 is responsible for mediatingM1-activated microglia-induced
neurotoxicity, and its overexpression induces axonal degeneration in vitro. These studies
suggest that TTBK1 is an important molecule for the inﬂammatory axonal degeneration,
which may be relevant to the pathobiology of tauopathy including AD.
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TAUOPATHY AND TAU KINASES
The microtubule-associated protein tau (MAPT) is a physio-
logical component of the microtubule architecture of neuronal
axons (Weingarten et al., 1975). Hyperphosphorylated tau pro-
tein (pTau) is a principal component of neuroﬁbrillary tangles
(NFTs), which are a hallmark of tauopathies, such as Alzheimer’s
disease (AD) and frontotemporal dementia (FTD; Grundke-Iqbal
et al., 1986; Wolozin et al., 1986; Iqbal et al., 1989). The human
tau gene is segregated to a rare form of familial FTD with
Parkinsonism linked to chromosome 17 (FTDP-17), demonstrat-
ing MAPT as a causative gene of neurodegenerative disorders
(Hong et al., 1998; Hutton et al., 1998). The mechanism of
NFT formation is centered around tau phosphorylation, mono-
ubiquitination, and conformational changes of the protein from
highly extended native form to paired helical ﬁlament (Ihara et al.,
1986; Kosik et al., 1986). pTau found in NFT suggests that there
is an imbalance between the tau kinase and phosphatase activ-
ities or some dysfunction in the clearance of pTau in affected
human brain (Takashima et al., 1995; Gong et al., 2000; Jinwal
et al., 2013). Tau protein is phosphorylated by multiple protein
kinases, such as glycogen synthase kinase 3-β (GSK3β) and cycline-
dependent kinase 5 (Cdk5; Ishiguro et al., 1991, 1992; Arioka
et al., 1993; Takashima et al., 1993). GSK3β and Cdk5 are sus-
pected to play a major role in pathological phosphorylation of
tau in the brain. As such, large efforts have been made to develop
inhibitors toward these kinases (Brunden et al., 2010). One of the
main disadvantages of targeting such kinases is their ubiquitous
expression in multiple peripheral tissues, which warrants serious
unwanted side effects. Brain-speciﬁc tau kinases are attractive tar-
gets for ameliorating the phosphorylation status of tau protein.
Through the complementary DNA library screening of brain-
speciﬁc kinases, we have identiﬁed tau-tubulin kinase 1 (TTBK1),
which is uniquely expressed in neurons in the central nervous
system (CNS) and can phosphorylate tau protein (Sato et al.,
2006).
TAU-TUBULIN KINASE FAMILY
The TTBK family consists of TTBK1 (1321 a.a.; Sato et al., 2006)
and TTBK2 (1244 a.a.; Houlden et al., 2007). These two kinases
belong to the casein kinase 1 (CK1) group, which contains CK1
(α1, α2, γ1, γ2, γ3, δ, and ε), TTBK (1 and 2), and vaccinia-
related kinase (VRK) 1–3 (Figure 1A; Manning et al., 2002; Sato
et al., 2006). CK1δ can phosphorylate tau in cultured cells and
is known to be up-regulated in AD brain (Li et al., 2004). The
alignment of the kinase domain of TTBK1 and CK1δ shows
38% identity and 52% similarity (Sato et al., 2006); therefore,
TTBK1 is the closest relative of CK1, but not a member of
CK1 family. The catalytic domain of TTBK1 is conserved in ver-
tebrates, C. elegans, and D. melanogaster (Figure 1B). TTBK1
and TTBK2 amino acid sequences are 60% identical and 71%
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FIGURE 1 | Dendrogram of CK1 group and sequence conservation of
TTBK1. (A) Phylogenetic tree of human casein kinase family. The scale
bar represents 0.1 amino acid substitution per site. Bootstrap values
(1,000 bootstrap iterations) are indicated. VRK3 was removed due to
low homology to other kinases in CK1 family. (B) Alignment of human
and mouse TTBK1, and C. elegans and D. melanogaster TTBK amino
acid sequences. TTBK1 34–308, dual-kinase domain; 309–732, conserved
domain A; 733–770, polyglutamate domain; 771–1321, conserved
domain. (C) Dendrogram of TTBK family among species. D_RERIO;
zebraﬁsh, X_TROPICALIS; Western clawed frog, G_GALLIS; chicken,
M_MULATTA; rhesus macaque, R_NORVEGICUS; rat, C_ELEGANS;
roundworm, C_CAPITATA; Mediterranean fruit ﬂy, D_MELANOGASTER;
common fruit ﬂy. The number after each name indicates the branch
length.
similar in the TTBK1 14–577 and TTBK2 1–589 regions. Their
kinase domains (TTBK1 35–294 and TTBK2 21–280) are highly
homologous (88% identity and 96% similarity). The rest of the
sequences have no homology except a small domain (TTBK1
1053–1117 and TTBK2 942–1006 with 43% identity and 58%
similarity). TTBK1 and TTBK2 are distinctly conserved among
vertebrates from zebraﬁsh (D. rerio) to human (Figure 1C). How-
ever, TTBK homologs in C. elegans (TTBK), C. capitata (TTBK1),
andD.melanogaster (ASATOR)only conserve the catalytic domain
of TTBK1 or TTBK2 (Figure 1C). Since the catalytic domain
of TTBK1 and TTBK2 are highly homologous, this suggests
that TTBK1 and TTBK2 genes are diversiﬁed from a common
shorter TTBK gene during the evolution from invertebrates to
vertebrates.
TTBK2
TTBK2 GENE AND PROTEIN FUNCTION
The human TTBK2 gene (Gene ID: 146057) is positioned on
chromosome 15q15.2, and consisted with nine exons and 10
introns with a complementary DNA (cDNA) length of 6192bp.
TTBK2 was previously extracted from bovine and mouse brain
as a 36 kDa protein, and it phosphorylates tau protein at Ser208
and Ser210 (Takahashi et al., 1995; Tomizawa et al., 2001). TTBK2
is ubiquitously expressed in multiple tissues, such as placenta,
liver, skeletal muscle, pancreas, heart, and brain. There is espe-
cially higher expression in the Purkinje cells and granular cell
layer of the cerebellum, hippocampus, midbrain and substantia
nigra (Houlden et al., 2007), on the other hand, lower expres-
sion is shown in the cortex. At a protein level, TTBK2 is highly
expressed in brain and testis, which corresponds to the elevated
kinase activity in these tissues (Bouskila et al., 2011).
A recombinant kinase domain of mouse TTBK2 corresponds
to human TTBK2 1–316 residues (98% identity), and the kinase
domain (residues 1–331) of human TTBK2 was expressed in
insect cells with a baculovirus overexpression system and crys-
tallized (Kitano-Takahashi et al., 2007). Diffraction data were
collected to 2.9 Å resolution, but so far no publication is
available for the structural information. Consensus phospho-
rylation sites for CK1 isoforms is S/Tp-X-X-S/T, where S/Tp
refers to a phosphoserine or phosphothreonine: X refers to any
amino acid and the underlined residues refer to the target site
(Flotow and Roach, 1989; Flotow et al., 1990; Nakielny et al.,
1991). The priming phosphorylation site is at the −3 position
in the case of CK1. However, the preferred priming phos-
phorylation site is the tyrosine residue at the +2 position for
TTBK2 (S/T-X-Yp), and either serine or threonine residue on
the +2 position rather diminish the priming effect (Bouskila et al.,
2011).
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Multiple biological functions of TTBK2 have recently been
identiﬁed: TTBK2 is critical in the initiation of ciliogenesis, which
is important for sonic hedgehog developmental pathway (Goetz
et al., 2012; Tanos et al., 2013; Ye et al., 2014). TTBK2 may also
play a role in mitosis: Asator, a TTBK2 homolog in Drosophila, is
localized in themitotic spindle and directly interacts with the spin-
dle matrix protein Megator (Qi et al., 2009). TTBK2 may also be
involved in anti-cancer drug resistance: TTBK2 increases the cell
surface number of sodium-coupled glucose transporter (SLC5A1)
in cancer cells and confers cell survival against anti-cancer drugs
(Almilaji et al., 2013). These studies indicate the diverse functions
of TTBK2 in embryogenesis, mitosis and cell survival (Table 1).
Further studies will be necessary for characterizing the function
of TTBK2 in the CNS.
TTBK2 MUTATION IN SPINOCEREBELLAR ATAXIA 11 (SCA11)
Spinocerebellar ataxias (SCAs) are a heterogeneous group of
neurodegenerative disorders characterized by poor coordination,
abnormal eye movements, impairment of speech and swallowing,
and pyramidal signs (Schols et al., 2004). Almost all affected indi-
viduals show cerebellar atrophy when tested by MRI. SCA11 is a
pure progressive cerebellar ataxia that has been genetically linked
to human chromosome 15q14–21 (Worth et al., 1999). The mean
age of onset for the disease is 24.2 ± 8.4 years, ranging from 15–
43. SCA11 is an autosomal dominant form of cerebellar ataxia and
so far two families have been identiﬁed: a Caucasian family that
traces its earliest known British ancestry to the 19th century and
another of Pakistani ancestry, with ﬁve affected individuals present
over three generations (Figure 2A; Houlden et al., 2007; Johnson
et al., 2008). Both families show genetically linked mutations in
the TTBK2 gene, with the Caucasian family having a one-base
insertion of an adenosine in exon 13 at nucleotide 1329 (codon
444), creating a premature stop site (TGA) in the mRNA at codon
450 and truncating the normal protein from 1,244 to 450 amino
acids (Figure 2B, 1329InsA). The same mutation was also found
in another case of SCA11 by next generation sequencing (Németh
et al., 2013). The Pakistani family was associated with a frameshift
deletion of two bases (GA) in exon 13 of TTBK2 at nucleotides
1284/1285, codons 428 and 429, creating a premature stop site
(TGA) in the mRNA at codon 449 (Figure 2B, 1284/85DelAG).
Transient expression study shows that SCA11-linked mutations
of TTBK2 dramatically reduce the kinase activity to 10% of full-
length TTBK2 and promote their nuclear localization (Bouskila
et al., 2011). TTBK2-1329InsA-knockin mice also show reduced
kinase activity in vivo (Bouskila et al., 2011). Since kinase-negative
TTBK2 mutant also shows nuclear localization, the reduction of
kinase activity and autophosphorylation may regulate its subcel-
lular localization. The effect of TTBK2 nuclear localization on
neurotoxicity is unknown. These mutations have no effect on the
half-life of expressed TTBK2 proteins, which is approximately 24 h
(Bouskila et al., 2011).
Neuropathological examination with TTBK2 mutated brain
also had been carried out (Houlden et al., 2007). The brain
macroscopically showed intense atrophy of the cerebellum. Micro-
scopically, severe and almost complete loss of Purkinje cells and
a signiﬁcant loss of cerebellar granule cells have been shown. The
medullary tegmentum, nigra, midbrain tegmentum and puta-
men presented NFTs, neuropil threads and tau-positive neuritis.
Pre-tangles and NFTs, as well as oligodendrocyte tau-positive ﬁla-
mentous inclusions, were found in the globus pallidus. There also
exist pathological aging, sparse tangles and β-amyloid-positive
plaques in the neocortex, hippocampus, and transentorhinal,
entorhinal, and insular cortices. No plaques were present in the
cerebellum. Although the brain that has the TTBK2 mutation
(codon 444) showed cell loss in the cerebellum, there is no other
visible pathology (Houlden et al., 2007). Therefore, the degree of
TTBK2 gene expression did not associate with pathology in the
cerebellum although the gene was highly expressed.
TTBK2 truncation mutations found in the SCA11 families
resulted in a shorter half-life of mRNA as compared to wild-
type TTBK2 mRNA, suggesting the reduction in expression of
TTBK2 by the mutations (Houlden et al., 2007). Kraemer et al.
(2006) reported the role of TTBK2 in the tau pathway using
RNA interference experiments in C. elegans. Treating worms
with short interfering RNA to a C. elegans homolog of TTBK2
(TTBK) in the presence of an FTDP-17 mutant tau transgene
enhanced the uncoordinated movement phenotype (dyskinesia).
Taken together, these data suggest that reduction inTTBK2 expres-
sion levels may accelerate tau-related pathogenesis. In accord,
TTBK2-knockin mice expressing an SCA11 disease-causing muta-
tion show the reduction of endogenous TTBK2 kinase activity
(Bouskila et al., 2011). The SCA11 mutation homozygosity causes
lethality at embryonic day 10. These studies demonstrate that
SCA11-linkedTTBK2mutation is a loss-of-functionmutation and
the TTBK2 gene is essential in embryogenesis. This is consistent
with the recent series of ciliogenesis studies on TTBK2 knockout
mice (Goetz et al., 2012; Tanos et al., 2013; Ye et al., 2014).
In addition to the two reported mutations on TTBK2 in SCA11
cases, a recent study also identiﬁed 1306_1307delGA mutation
in exon 2 of one German and one French SCA11 cases (Bauer
Table 1 | Summary ofTTBK family.
Genes Chromosomal loci Disease linkage Expression Function Reference
TTBK1 6p21.1 AD (GWAS) The CNS (neuron) Cdk5/GSK3β activation
Tau aggregation
Axonal degeneration
Sato et al. (2008)
Xu et al. (2010b), Lund et al. (2013)
Asai et al. (2014)
TTBK2 15q15.2 SCA11 Ubiquitous Ciliogenesis
Mitosis
Cell survival
Goetz et al. (2012), Ye et al. (2014)
Qi et al. (2009)
Almilaji et al. (2013)
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FIGURE 2 | Pedigrees of SCA11 families 1 and 2. (A) The family trees
are anonymized, as there are many at-risk individuals. Males or females
are given as a diamond, blackened symbols indicate affected
individuals, a slash through the symbol indicates the individual is
deceased and an arrow indicates the family proband. Adapted from
Houlden et al. (2007). (B) Sequence alignment of human TTBK1 and
TTBK2 and sites of SCA11-linked TTBK2 mutations. Gray background
shows putative catalytic domain (PHA02882). Accession number:
BAE78660 (human TTBK1) and EAW92583 (human TTBK2). *Denotes
translational termination.
et al., 2010). This also leads to the premature stop codon after the
catalytic domain sequence. Three additional missense mutations
were found in SCA11 cases (L8P, E842G, and R1110H; Edener
et al., 2009). However, these mutations are outside of the catalytic
domain and also reported in the 1000 Genomes project, suggest-
ing them as common variants. In addition, recent 1000 Genomes
project identiﬁed a total of 12,708 somatic variations in human
TTBK2 gene, including 301 missense variants, 11 stop-gained
variants, 17 frameshift variants, 32 splicing variants, 30 5′UTR
variants, and 83 3′UTR variants. This results in seven different
splicing variants of TTBK2 genes (TTBK2-1, TTBK2-2, TTBK2-
3, TTBK2-7, TTBK2-6, TTBK-8, and TTBK2-5) and 6 different
amino acid sequences (TTBK2-5 has no protein product), whose
lengths are 1244, 478, 443, 117, 143 and 84, respectively. Only
TTBK2-1, TTBK2-2, and TTBK2-3 genes encode the catalytic
domain. Interestingly, among the 11 stop-gained variants, six
are terminated at Glu19 (MSGGGEQPDILSVGILVKE/∗), suggest-
ing the somatic loss-of-function mutation. Although none of the
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somatic loss-of-function mutations is linked to human diseases,
these data suggest thatTTBK2 loci are highly susceptible to somatic
mutations and may be associated with human diseases related to
cancer or neurodegenerative disorders.
TTBK1
TTBK1 GENE EXPRESSION AND DISTRIBUTION
Human TTBK1 gene (Gene ID: 84630), which we originally
cloned, is positioned on chromosome 6p21.1 and consists of 14
exons and 15 introns with a cDNA length of 6932bp (Sato et al.,
2006). The TTBK1 protein (UniProt ID: Q5TCY1) consists of
1,321 amino acids and has a kinase domain and a polygluta-
mate domain in the middle region of the sequence (Figure 1B).
TTBK1 isoform2 was also recently identiﬁed (TTBK1–2, UniProt
ID: Q5TCY1–2), which consists of 621 amino acids and share
amino acids 52–540 and 1194–1229 of isoform1. Since isoform2
lacks in the N-terminal region of the consensus kinase domain, it
likely has no kinase activity. TTBK1 mRNA was detected in cor-
tex and cerebellum, and in fetal brain (Sato et al., 2006). In situ
hybridization study on mouse brains detected strong expression
of TTBK1 gene expression in the CA1 pyramidal cell layer of the
hippocampus, perinuclear, and cytoplasmic regions of the large
cortical pyramidal cell in the temporal cortex, and the Purkinje
cell layer of the cerebellum (Sato et al., 2006). Recent independent
studies also conﬁrm the speciﬁc expression of TTBK1 mRNA in
neuronal layers of human brain as determined by in situ hybridiza-
tion (Lund et al., 2013). Immunohistochemistry of human brain
with several TTBK1 antibodies produced particularly strong gran-
ular staining in the apical and basal dendrites and in deposits in
the neuronal cell soma.
Tau-tubulin kinase 1 protein expression is signiﬁcantly upreg-
ulated in AD brains (Sato et al., 2008). Immunohistochemical
analysis of ADbrains shows thatTTBK1 co-localizeswith pSer422-
positive pre-tangles but not with thioﬂavin-S-positiveNFTs (Lund
et al., 2013). pSer422 antibody identiﬁes a rare population of AT8-
unlabeled neurons, which scatter throughout the hippocampal
formation and the entorhinal cortex. These data suggest that
TTBK1 may play a signiﬁcant role in pre-tangle formation by
tau phosphorylation at Ser422 in the entorhinal cortex and hip-
pocampus. This is in line with a previous report claiming that
Ser422 becomes phosphorylated earlier in the development of an
NFT, preferentially marking intracellular NFTs (Augustinack et al.,
2002).
In addition, genetic variations of the TTBK1 gene (SNPs
rs2651206, rs10807287, and rs7764257) are associated with late-
onset Alzheimer’s disease (LOAD) in two large cohorts of Spanish
and Chinese populations (Vazquez-Higuera et al., 2011; Yu et al.,
2011), further validating the importance of the TTBK1 gene in the
development of tauopathy and AD pathogenesis (Cuny, 2009).
These ﬁndings are summarized in Table 1. Recent 1000 Genomes
project identiﬁed a total of 1,650 variations in human TTBK1
gene, including 194 missense variants, ﬁve stop-gained variants,
nine frameshift variants, 23 splicing variants, 8 5′UTR variants,
and 32 3′UTR variants. The number of TTBK1 variants was much
smaller than that of TTBK2 variants. The ﬁve stop variants are
terminated at Arg650, Arg599, Gln686, Glu753, and Ser1067.
All of them still encode the catalytic domain and are possibly
gain-of-function mutations, since shorter amino acid sequences
are generallymore efﬁcient in protein translations. These data sug-
gest that more genetic associations to TTBK1 gene may be found
in human diseases.
TAU AND TUBULIN PHOSPHORYLATION
Tau-tubulin kinase 1 directly phosphorylates itself, tau and
tubulin. Furthermore, we determined the exact human tau 40
(htau40) phosphorylation sites in vitro by phosphopeptide map-
ping with liquid chromatography and tandem mass-spectrometry
(LC/MS/MS; Sato et al., 2006). The htau40 phosphorylation at
Tyr197, Ser198, Ser199, Ser202 and Ser422, which have all been
reported as phosphorylation sites in PHF-tau (Iqbal et al., 1989;
Morishima-Kawashima et al., 1995a,b; Hanger et al., 1998; Vega
et al., 2005). These results show that TTBK1 is a critical tau pro-
tein kinase for the phosphorylation of PHF-speciﬁc sites. Direct
phosphorylation of Ser422 andAT8 epitopes (Ser202 and Thr205)
by TTBK1 was also independently demonstrated (Lund et al.,
2013). pSer422 is a very speciﬁc marker for pathological PHF-
tau, since little phosphorylation is present in the normal adult
brain (Hasegawa et al., 1996). TTBK1 is one of the few kinases,
along with the microtubule-associated protein kinases, that can
phosphorylate tau protein at Ser422 (Reynolds et al., 1997; Sato
et al., 2002, 2006).
For the crystallography of TTBK1, TTBK1 (1–313) and
(14–313) fragments were expressed in E. coli and insect cells,
which were found as multi-phosphorylated forms (Xue et al.,
2013). To avoid this problem, TTBK1 protein was co-expressed
with lambda phosphatase, by which TTBK1 was dephosphory-
lated and was subsequently co-crystallized with two high-afﬁnity
ATP-competitive inhibitors: 3-[(6,7-dimethoxyquinazolin-4-
yl)amino]phenol (compound 1) and methyl 2-bromo-5-(7H-
pyrrolo[2,3-d]pyrimidin-4-ylamino)benzoate (compound 2).
Two positive clusters identiﬁed on the surface of TTBK1 indicate
putative binding sites for the “primed” substrate, suggesting that
TTBK1 favors “primed” pre-phosphorylated substrates. The con-
sensus phosphorylation sites of TTBK1 have not been character-
ized. Considering the very high homology in the kinase domain of
TTBK1 and TTBK2 (Figure 2B), they may share the same consen-
sus phosphorylation sites (S/T-X-Yp) of the substrate. The crys-
tallography shows that compound 1 enters the selectivity pocket,
while compound 2 does not reach the selectivity pocket and shows
slow binding kinetics as determined by surface plasmon resonance
analysis (Xue et al., 2013). The distinct structural-kinetic behavior
could be used for the design of selective TTBK1 inhibitors. The
other group also just published a crystal structure of TTBK1 (14–
343), which was puriﬁed from baculovirus-infected sf9 insect cells
(Kiefer et al., 2014). They report co-crystalization with compound
3, 3-({5-[(4-amino-4-methylpiperidin-1-yl)methyl]pyrrolo[2,1-
f][1,2,4]triazin-4-yl}amino)-5-bromophenol, a TTBK1 inhibitor
with IC50 of 170 nM.Due to the structural and sequence similarity
of TTBK1 and TTBK2, TTBK1/2 selectivity may be still difﬁcult
to achieve.
TTBK1 TRANSGENIC MOUSE STUDY
A TTBK1 transgenic mouse model harbors the entire human
TTBK1 genomic DNA, which consists of a CpG island in the
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5′ non-coding region, 13 introns and 14 exons, spanning 57
kb in chromosome 6p21.1 (Sato et al., 2008). Transgenic human
TTBK1 mRNA is expressed in cerebellum, cortex and spinal cord,
and TTBK1 protein is expressed in a similar pattern in TTBK1
transgenic mice (Sato et al., 2008).
Immunohistochemistry of TTBK1 transgenic mice exhibited
very speciﬁc expression of TTBK1 protein in the perforant path
region of subiculum, layer II/III of the entorhinal cortex and
the external pyramidal layer of the visual cortex as compared to
the age-matched non-Tg mice (Sato et al., 2008). TTBK1 trans-
genic mice showed strong phospho-neuroﬁlament staining in
the entorhinal cortex, visual cortex and subiculum, suggesting
neuronal dysfunction in these regions. Enhanced microgliosis
was observed in the hippocampus and visual cortex, as well as
astrogliosis in the visual cortex of the TTBK1 transgenic mouse
brains (Sato et al., 2008).
The most striking phenotype of the TTBK1 transgenic mice
is the loss of spatial learning at 9–10 months of age as deter-
mined by the 6-arm radial arm water maze test (Sato et al., 2008).
TTBK1 transgenic mice showed increased levels of the Cdk5
co-activators p35 and p25; enhanced calpain-1 activity, which
cleaves p35 into p25; and enhanced p35-associated Cdk5 activity.
Cdk5 and calpain-1 closely regulate the post-synaptic levels of the
NMDA receptor (NR) subunits, especially NR2B, and affect hip-
pocampal long-term potentiation and spatial learning (Hawasli
et al., 2007; Zhang et al., 2008). Calpain-1 also cleaves NR2B
directly and reduces its cell surface expression (Simpkins et al.,
2003; Wu et al., 2005, 2007). Consistently, we observed signiﬁ-
cantly reduced expression of NR2B in the hippocampus of TTBK1
transgenic mice as compared to age-matched non-Tg mice. We
further conﬁrmed that transient overexpression of TTBK1 down-
regulated NR2B expression in primary cultured mouse cortical
neurons, which were sensitive to a calpain inhibitor or the silenc-
ing of endogenous Cdk5 by Cdk5-targeting siRNA transfection.
We have also found that G-actin but not F-actin directly bind to
Cdk5 and prevent its activation by p35 or p25 (Xu et al., 2010a).
Collectively, we have developed the following hypothesis in the
scheme (Figure 3): inactive μ-calpain forms a stable complex with
calpastatin, and TTBK1 may dissociate the complex via direct or
indirect phosphorylation of calpastatin, leading to the activation
of calpain (Figure 3A). FAA (F-actin and alpha-actinin complex)
forms a stable complex with p35 and G-actin is associated with
Cdk5, preventing the Cdk5/p35 complex formation in the nor-
mal state (Figure 3B). TTBK1 may phosphorylate alpha-actinin,
leading to dissociation of p35 from FAA and the formation of
the Cdk5/p35 complex via dissociation of Cdk5 from G-actin.
The Cdk5/p35 complex serves as scaffolding molecules to generate
the NR2B/Cdk5/p35/calpain complex as reported (Hawasli et al.,
2007) and mediate the cleavage of the C-terminal region of NR2B,
which is a critical region for post-synaptic membrane retention
of NR2B. The loss of the C-terminal region leads to endocyto-
sis and degradation of NR2B (Figure 3C). This multi-step signal
is composed of a new calpain activation mechanism and a new
regulation of Cdk5/p35 complex formation by FAA, and is consis-
tent with the recent report on calpain-mediated NR2B processing
(Hawasli et al., 2007). In addition, activated calpain cleaves the
N-terminal of p35 to generate p25, a more potent Cdk5 activator.
p25, however, lacks the N-terminal region of p35 necessary for
the association with alpha-actinin (Dhavan et al., 2002) and thus
can form a Cdk5/p25 complex independent of FAA or G-actin
FIGURE 3 | Hypothetical regulation of μ-calpain activation, Cdk5/p35
complex formation, and NR2B degradation by TTBK1. (A) Inactive
μ-calpain forms a stable complex with calpastatin, and TTBK1 dissociates
the complex via direct or indirect phosphorylation of either μ-calpain or
calpastatin, leading to the activation of μ-calpain. (B) FAA (F-actin and
α-actinin complex) forms a stable complex with p35. G-actin is associated
with Cdk5. These two statuses prevent the Cdk5/p35 complex formation
in the normal state. TTBK1 may phosphorylate α-actinin, leading to
dissociation of p35 from FAA and the formation of the Cdk5/p35 complex
via dissociation of G-actin from p35. (C) The Cdk5/p35 complex serves as
scaffolding molecules to generate the NR2B/Cdk5/p35/μ-calpain complex
and mediates the cleavage of the C-terminal region of NR2B. The
C-terminus-lacking NR2B fails to be retained in post-synaptic membrane
and undergoes endocytic degradation pathway.
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association with Cdk5, leading to dysregulated activation of Cdk5.
This will further enhance NR2B degradation.
TAU/TTBK1 DOUBLE TRANSGENIC MOUSE STUDY
Crossing of TTBK1 transgenic mice with JNPL3 [P301L tau
mutant mice (Lewis et al., 2000)] results in enhanced intraneu-
ronal accumulation of phosphorylated tau at multiple sites (AT8,
12E8, PHF-1, and pS422) in cortical and hippocampal regions.
Testing of TTBK1/JNPL3 and JNPL3 mice at 5–11 months of age
with accelerated rotarod tests demonstrated that TTBK1/JNPL3
mice showed signiﬁcantly shorter retention time compared to
JNPL3 mice as early as 7 months of age (Xu et al., 2010b). We have
also detected the signiﬁcant reduction in forelimb grip strength in
TTBK1/JNPL3 mice as compared to JNPL3 littermates starting at
6 months of age, suggesting the sensorimotor or neuromuscular
dysfunction in TTBK1/JNPL3 mice. These ﬁndings prompted us
to examine the neuropathology of motor neurons in the anterior
horn of spinal cords at the L4–L5 region. TTBK1/JNPL3 mice
also show increased accumulation of oligomeric tau protein in the
forebrain and spinal cord, and enhanced reduction in motor neu-
rons in the anterior horn of the lumbar spinal cord, which are
associated with neuroinﬂammation. This suggests that TTBK1 is
signiﬁcantly involved in progression of tauopathy.
TAU AND NEUROINFLAMMAITON
Recent studies demonstrated that neuroinﬂammation may
play a signiﬁcant role in the pathophysiology of tauopathies
(Gebicke-Haerter, 2001; Ishizawa and Dickson, 2001; Gerhard
et al., 2006). In the LOAD brains, glial activation (both astrocytes
and microglia) has a signiﬁcant linear positive correlation with
disease course and NFT formation (Serrano-Pozo et al., 2011).
Enhanced pro-inﬂammatory activation of microglia by disruption
of CX3CR1, an anti-inﬂammatory fractalkine receptor, accelerates
tangle formation in tau mouse models (Bhaskar et al., 2010). In
accord, immunosuppressant drug FK506 can attenuate microglial
activation and delayed the tau-related neuropathology in P301S
tau mice (Yoshiyama et al., 2007). These studies suggest that pro-
inﬂammatory activation of microglia plays a critical role in the
onset and progression of tauopathy. The neuroinﬂammation is
orchestrated by both resident microglia and inﬁltrated periph-
eral macrophages, as they can be recruited by chemokines such
as CCL2, which are highly up-regulated in the LOAD brain (Xia
and Hyman, 1999; Grammas and Ovase, 2001; Lue et al., 2001;
Sun et al., 2003; Pola et al., 2004; Janelsins et al., 2005; Yamamoto
et al., 2005; Galimberti et al., 2006; El Khoury et al., 2007; Hickman
et al., 2008; Semple et al., 2010). However, the mechanism of how
neuroinﬂammation accelerates tauopathy development is poorly
understood.
Neuroinﬂammation is triggered by the innate immune
response, in which mononuclear phagocytes play a major
role. When these phagocytes recognize pathogen- or damage-
associated molecular pattern molecules (PAMPs and DAMPs),
they become “activated,” and this activation can be classiﬁed
into two phenotypes: classical/pro-inﬂammatory (M1) and
alternative/anti-inﬂammatory activation (M2; Gordon and Mar-
tinez, 2010). M1-skewed activation of mononuclear phago-
cytes causes the release of pro-inﬂammatory cytokines, such as
interferon (IFN)-γ, tumor necrosis factor (TNF)-α, interleukin
FIGURE 4 | Scheme of neuroinflammation and neurodegeneration in
JNPL3 and TTBK1/JNPL3 mice. In JNPL3 mice, CD11c+ neuroprotective
microglia accumulate in the gray matter of the ventral horn, thereby
protecting from accelerated neurodegeneration. Conversely, in
TTBK1/JNPL3 mice, the cell population is shifted from CD11c+ microglia
to M1-skewed inﬁltrating NOS2+CD169+ monocytes, resulting in
enhanced neuroinﬂammation and accelerated motor neuron loss. Adapted
from Asai et al. (2014).
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(IL)-6, IL-12, IL-1β, and IL-23, and reactive oxygen/nitrogen inter-
mediates induced by the expression of nitric oxide synthase (NOS)
and NADPH oxidases (NOXes; Mantovani et al., 2002; Brown,
2007; Benoit et al., 2008). In contrast, M2-skewed activation is
characterized by abundant levels of non-opsonic receptors (e.g.,
the mannose receptor) and production of high levels of anti-
inﬂammatory cytokines (Mantovani et al., 2004). However, there is
no comprehensive characterization of CNS mononuclear phago-
cytes and their activation status (M1 or M2) in tauopathy-related
neurodegenerative disorders.
Our recent study demonstrated that (1) TTBK1 accelerates
motor neuron loss in the spinal cord of JNPL3 mice; (2) JNPL3
mice show mostly M2-skewed microglial accumulation in the
spinal cord ventral horn, whereas TTBK1/JNPL3 mice show M1-
skewed inﬁltratingmonocytes in the same region. These cell can be
regognized asCD169+ (sialoadhesin+) cells; (3) TTBK1upregula-
tion reduces the axonal length, whereas resting microglia enhance
neurite extension; and (4) motor neurons are sensitive to neuro-
toxicity induced by M1-activated microglia, and this is dependent
on endogenous TTBK1 gene expression (Asai et al., 2014). While
these are multifaceted ﬁndings and it is difﬁcult to draw a sim-
ple conclusion, Figure 4 depicts our proposed mechanism of how
TTBK1 initiates axonal degeneration and subsequent inﬂamma-
tory status and neurodegeneration: in JNPL3 mice, motor neuron
loss is evident in the ventral horn of the lumbar spinal cord, which
is accompanied by accumulation of CD11c+ neuroprotective
microglia, thereby limiting neurodegeneration. TTBK1/JNPL3
mice, on the other hand, show a dramatic conversion of the
cell population from CD11c+ microglia to M1-skewed inﬁltrating
CD169+ monocytes. This could be due to the accelerated neu-
rodegeneration by TTBK1 upregulation and enhanced generation
of DAMPs (M1-skewing ligands) from degenerating motor neu-
rons, which leads to pro-inﬂammatory activation, generation of
CCL2 chemokine and inﬁltration of peripheral monocytes. This
may lead to the acceleration of neurodegeneration via bystander
killing of neurons. Overall, these data support the idea that TTBK1
plays a signiﬁcant role in facilitating inﬂammatory mononuclear
phagocyte-mediated neurotoxicity and subsequent inﬁltration of
peripheral monocytes into the CNS. More study will be necessary
to understand the exact molecular mechanism.
SUMMARY
Large efforts have been made to develop inhibitors toward GSK3β
and Cdk5 as primary tau kinases (Brunden et al., 2010). One
of the main disadvantages of targeting the two kinases is their
ubiquitous expression in multiple peripheral tissues, which war-
rants serious unwanted off-target side effects in multiple tissues.
TTBK1 therefore is a potentially attractive candidate for pharma-
cological inhibition because of its apparent restricted expression
to neurons in the CNS. Overexpression of TTBK1 was sufﬁcient in
inducing spatial learning impairment in mice, which is associated
with enhanced Cdk5 activity and reduction in cell surface level
of NR2B. Over-expression of TTBK1 transgene in JNPL3 mice
resulted in accumulation of pre-tangle forms of tau. In addition,
TTBK1 expression plays a unique role in accelerating motor neu-
ron degeneration and neuroinﬂammation in JNPL3 mice. One
would therefore expect that an enhanced expression or activation
of TTBK1 would lead to increased tau phosphorylation and pre-
dispose tau to pre-tangle formation. Indeed, genetic variations in
TTBK1, which are thought to result in decreased TTBK1 activ-
ity, can decrease the risk of AD (Vazquez-Higuera et al., 2011;
Yu et al., 2011). Thus, TTBK1 is a novel therapeutic target of
neuroinﬂammation-associated neurodegeneration, such as AD,
FTD, and tauopathy-relatedALS complex. Further studies are nec-
essary to characterize the association of TTBK1 polymorphism,
TTBK1 expression, pre-tangle formation and neuroinﬂammation
inAD cases, and to see if reduction in TTBK1 level by TTBK1 gene
targeting or silencing delays the progression of tau pathology in
established tau mouse models for pre-clinical validations.
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